Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations

被引：0

作者：

Popovici-Muller, Janeta ^{[1
]}

Lemieux, Rene ^{[2
]}

Saunders, Jeffrey ^{[3
]}

Salituro, Francesco ^{[4
]}

Yen, Katharine ^{[1
]}

Straley, Kimberly ^{[5
]}

Tobin, Erica ^{[1
]}

Wang, Fang ^{[1
]}

Gross, Stefan ^{[1
]}

Artin, Erin ^{[1
]}

Dang, Lenny ^{[1
]}

Yang, Hua ^{[1
]}

Utley, Luke ^{[6
]}

Chen, Yue ^{[1
]}

Olaharski, Andrew ^{[1
]}

Silverman, Lee ^{[1
]}

Agresta, Sam ^{[1
]}

Su, Michael ^{[1
]}

Biller, Scott ^{[1
]}

机构：

[1] Agios Pharmaceut, Cambridge, MA USA

[2] KSQ Therapeut, Cambridge, MA USA

[3] Resilience Therapeut, Boston, MA USA

[4] Sage Therapeut, Cambridge, MA USA

[5] Vertex Pharmaceut, Boston, MA USA

[6] Alnylam Pharmaceut, Cambridge, MA USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

268

引用

页数：1

共 50 条

[1] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Popovici-Muller, Janeta
Lemieux, Rene M.
Artin, Erin
Saunders, Jeffrey O.
Salituro, Francesco G.
Travins, Jeremy
Cianchetta, Giovanni
Cai, Zhenwei
Zhou, Ding
Cui, Dawei
Chen, Ping
Straley, Kimberly
Tobin, Erica
Wang, Fang
David, Muriel D.
Penard-Lacronique, Virginie
Quivoron, Cyril
Saada, Veronique
De Botton, Stephane
Gross, Stefan
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Kim, Hyeryun
Jin, Shengfang
Gu, Zhiwei
Yao, Gui
Luo, Zhiyong
Lv, Xiaobing
Fang, Cheng
Yan, Liping
Olaharski, Andrew
Silverman, Lee
Biller, Scott
Su, Shin-San M.
Yen, Katharine
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
[2] Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
DiNardo, Courtney D.
de Botton, Stephane
Stein, Eytan M.
Roboz, Gail J.
Swords, Ronan T.
Pollyea, Daniel A.
Fathi, Amir T.
Collins, Robert
Altman, Jessica K.
Flinn, Ian W.
Mannis, Gabriel N.
Mims, Alice S.
Foran, James M.
Pigneux, Arnaud
Prince, Gabrielle T.
Uy, Geoffrey L.
Tallman, Martin S.
Kantarjian, Hagop M.
Liu, Hua
Attar, Eyal C.
Sacolick, Jennifer
Yen, Katharine
Hurov, Jonathan B.
Choe, Sung
Wu, Bin
Stone, Richard M.
BLOOD, 2016, 128 (22)
[3] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
De la Fuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory M.
Burris, Howard
Janku, Filip
Huang, Ray
Young, Robert J.
Ellingson, Benjamin
Nimkar, Tara
Jiang, Liewen
Ishii, Yuko
Choe, Sung
Fan, Bin
Steelman, Lori
Yen, Katharine
Bowden, Chris
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2017, 19 : 10 - 11
[4] AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
Ishii, Yuko
Sigel, Carlie
Lowery, Maeve A.
Goyal, Lipika
Gliser, Camelia
Jiang, Liewen
Pandya, Susan
Bin Wu
Choe, Sung
Deshpande, Vikram
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[5] Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
Birendra, K. C.
DiNardo, Courtney D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (08): : 460 - 465
[6] AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
DeLaFuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory
Burris, Howard
Janku, Filip
Huang, Raymond
Young, Robert
Ellingson, Benjamin
Auer, Julia
Liu, Hua
Hurov, Jonathan
Yen, Katherine
Agresta, Sam
Attar, Eyal
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2016, 18 : 12 - 12
[7] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
de Botton, S.
Pollyea, D. A.
Stein, E. M.
DiNardo, C.
Fathi, A. T.
Roboz, G. J.
Collins, R.
Swords, R. T.
Flinn, I.
Altman, J. K.
Tallman, M. S.
Kantarjian, H.
Colby, K.
Fan, B.
Goldwasser, M.
Prahl, M.
Agresta, S.
Stone, R. M.
HAEMATOLOGICA, 2015, 100 : 214 - 215
[8] THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
Nicolay, Brandon
Narayanaswamy, Rohini
Aguado, Elia
Nagaraja, Raj
Murtie, Josh
Liu, Guowen
Ishii, Yuko
NEURO-ONCOLOGY, 2017, 19 : 86 - 86
[9] Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Gupta, Charu
Kaulfuss, Stefan
Goerlich, Kerstin
Othman, Basem
Chaturvedi, Anuhar
Heuser, Michael
ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1415 - 1417
[10] Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Charu Gupta
Stefan Kaulfuss
Kerstin Görlich
Basem Othman
Anuhar Chaturvedi
Michael Heuser
Annals of Hematology, 2020, 99 : 1415 - 1417

← 1 2 3 4 5 →